Ponatinib (Iclusig, AP24534) was recently FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial. B ecasue it not only attacks the CML mutation, BCR-ABL (including the T315I that other drugs doen affect it is an attarctive candidate for personalized use in conditions that display these mutations in the Personalized Medicine approach.
For Professional version see here
You can become a Site Sponsor. Or you may wish to support our work with a Donation.
Cancer Treatment Today
228 Park Ave S #70464
New York, NY 10003-1502
info@cancertreatmenttoday.org
Tel - 212-372-7263